RAMOSETRON (cas 132036-88-5) Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women
-
Add time:07/31/2019 Source:sciencedirect.com
Background & AimsPrevious studies have indicated that serotonin-3–receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and RAMOSETRON (cas 132036-88-5) has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women.
We also recommend Trading Suppliers and Manufacturers of RAMOSETRON (cas 132036-88-5). Pls Click Website Link as below: cas 132036-88-5 suppliers
Prev:RAMOSETRON (cas 132036-88-5) vs. RAMOSETRON (cas 132036-88-5) plus dexamethasone for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy: Prospective, randomized, and double-blind study
Next:Intravenous, Oral, and the Combination of Intravenous and Oral RAMOSETRON (cas 132036-88-5) for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Controlled Trial) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Inhibitory effect of the selective serotonin 5-HT3 receptor antagonist RAMOSETRON (cas 132036-88-5) on duodenal acidification-induced gastric hypersensitivity in rats08/05/2019
- Effect of RAMOSETRON (cas 132036-88-5) on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats08/04/2019
- Comparison of RAMOSETRON (cas 132036-88-5) with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery08/03/2019
- Comparison of RAMOSETRON (cas 132036-88-5), dexamethasone, and a combination of RAMOSETRON (cas 132036-88-5) and dexamethasone for the prevention of postoperative nausea and vomiting in Korean women undergoing thyroidectomy: A double-blind, randomized, controlled study08/02/2019
- Intravenous, Oral, and the Combination of Intravenous and Oral RAMOSETRON (cas 132036-88-5) for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Controlled Trial08/01/2019
- RAMOSETRON (cas 132036-88-5) vs. RAMOSETRON (cas 132036-88-5) plus dexamethasone for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy: Prospective, randomized, and double-blind study07/30/2019
- Effect of RAMOSETRON (cas 132036-88-5) on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea07/29/2019
- Effects of prophylactic RAMOSETRON (cas 132036-88-5) and ondansetron on corrected QT interval during general anesthesia07/28/2019
- Comparison of RAMOSETRON (cas 132036-88-5) With Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial07/27/2019